Exercise with GLP-1 Medications: Preserving Muscle

When patients start GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound), the dramatic weight loss numbers often overshadow an important concern: how much of that lost weight is fat, and how much is muscle? Research now makes clear that what you do in the gym — or don't do — has a measurable impact on body composition outcomes during GLP-1 therapy.

Evidence: "Lean soft tissue loss comprised 26%–40% of total weight lost in GLP-1 receptor agonist trials — a proportion that parallels caloric restriction alone without exercise." — Neeland IJ, et al. Diabetes, Obesity and Metabolism. 2024. DOI: 10.1111/dom.15728

This article synthesizes the latest clinical evidence on how structured exercise — particularly resistance training — combined with GLP-1 therapy produces superior outcomes compared to medication alone.

Why Muscle Loss Matters During GLP-1 Treatment

GLP-1 receptor agonists are remarkably effective at reducing body weight. In the STEP-1 trial, semaglutide 2.4 mg produced an average 15% reduction in body weight over 68 weeks. However, not all of that weight loss comes from fat.

When you lose weight rapidly through any mechanism — caloric restriction, surgery, or pharmacotherapy — your body draws on both fat stores and lean tissue. Lean mass includes muscle, bone, organs, and water. Preserving as much of this lean mass as possible matters for several reasons:

Resting metabolic rate: Muscle is metabolically active. Losing it slows metabolism, making weight regain more likely after stopping treatment.
Functional strength: Sarcopenia (muscle loss) impairs mobility, balance, and quality of life — especially in older adults.
Glucose metabolism: Skeletal muscle is the primary site of glucose disposal. More muscle means better insulin sensitivity.
Long-term weight maintenance: Body composition at the end of treatment is the strongest predictor of whether weight stays off.

The SEMALEAN study, a prospective trial of 115 patients treated with semaglutide 2.4 mg over 12 months, documented that while fat mass decreased significantly, patients who actively engaged in exercise showed markedly better muscle function outcomes — including a mean improvement in handgrip strength of +4.5 kg and a reduction in sarcopenic obesity prevalence from 49% to 33%.

Evidence: "Semaglutide 2.4 mg significantly improved muscle function (handgrip strength +4.5 kg) and reduced sarcopenic obesity prevalence from 49% to 33% at 12 months, with exercise playing a key moderating role." — Alissou, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70141

What the Research Says: Exercise + GLP-1 Synergy

Weight Maintenance After Stopping Medication

One of the most clinically important questions is: what happens when you stop a GLP-1 medication? Weight regain is common — but structured exercise during treatment significantly changes the long-term trajectory.

A 2024 randomized controlled trial published in eClinicalMedicine (The Lancet) followed adults with obesity through a year of active treatment with either a GLP-1 receptor agonist, a supervised exercise program, or both combined — and then tracked them for another year with no treatment. The combined group showed substantially better weight maintenance at 12 months post-treatment compared to either intervention alone.

Evidence: "Participants who combined GLP-1 receptor agonist treatment with supervised exercise maintained significantly greater weight loss and improved body composition 1 year after treatment cessation compared to either intervention alone." — eClinicalMedicine (The Lancet). 2024. DOI: 10.1016/j.eclinm.2024.102475

Cardiorespiratory Fitness Improvements

A 2025 secondary analysis of a randomized controlled trial published in Sports Medicine examined physical fitness outcomes in 193 adults with obesity who received GLP-1 therapy, exercise, or both combined during a weight maintenance phase. The findings were striking:

Pharmacotherapy alone produced minimal improvements in cardiorespiratory fitness (VO₂max)
Exercise alone significantly improved VO₂max and functional performance
Combined treatment yielded the greatest improvements in both fitness and body composition

This reinforces a key insight: GLP-1 medications address the hormonal and appetite dimension of obesity, while exercise addresses the fitness and muscle dimension. Neither intervention fully compensates for the other.

Evidence: "Structured exercise combined with GLP-1-based pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone." — Sports Medicine. 2025. DOI: 10.1007/s40279-025-02386-0

Can Exercise Preserve — or Even Build — Muscle?

A case series from researchers Tinsley and Nadolsky (2025) documented patients who prioritized lean mass preservation strategies during GLP-1 therapy. These patients exercised 4–7 days per week, with resistance training 3–5 days per week, and maintained protein intakes of 0.7–1.7 g/kg/day. The results were remarkable:

Weight loss ranged from 13% to 33% of body weight
One patient lost 8.7% of total weight as lean soft tissue (near-unavoidable in large weight loss)
Two patients actually increased lean soft tissue despite significant weight loss

This case series cannot establish causality, but it suggests that aggressive exercise and nutrition strategies can potentially offset the lean mass losses typical of GLP-1 therapy.

Evidence: "Patients engaging in resistance training 3–5 days/week during GLP-1 therapy showed variable lean mass outcomes, with two individuals increasing lean soft tissue despite 13%–33% total weight loss." — Tinsley GM, Nadolsky S. SAGE Open Medical Case Reports. 2025. PubMed

Resistance Training vs. Aerobic Exercise: Which Is Better?

Not all exercise is equal for muscle preservation. The literature consistently favors resistance training over aerobic exercise when the goal is minimizing lean mass loss during caloric restriction.

Resistance Training

Resistance training (weightlifting, bodyweight exercises, resistance bands) stimulates muscle protein synthesis, which counteracts the catabolic signals from caloric deficit and rapid weight loss. For patients on GLP-1 therapy:

Frequency: 3–5 sessions per week
Volume: 2–4 sets per major muscle group
Intensity: Moderate to high (60–85% of 1-rep max)
Exercises: Compound movements (squats, deadlifts, rows, presses) for maximum muscle stimulus per unit time

Aerobic Exercise

Cardio is valuable for cardiovascular health, metabolic syndrome reduction, and fitness — but it has a smaller effect on muscle preservation than resistance training. The combination approach is optimal:

Exercise Type	Fat Loss	Muscle Preservation	VO₂max	Bone Health
Resistance Training	Moderate	High	Low-Moderate	High
Aerobic	High	Low	High	Moderate
Combined	High	High	High	High

For patients with limited time, resistance training should take priority if the primary concern is body composition. A 3-day/week program of 45–60 minutes covers most of the benefit.

Practical Challenges: Exercise on GLP-1 Medications

Reduced Appetite and Energy

GLP-1 medications suppress appetite dramatically. This is beneficial for weight loss but creates a challenge: many patients don't feel hungry enough to fuel workouts adequately. Recommendations:

Time meals strategically: Eat a protein-rich meal 1.5–2 hours before training
Protein shakes: Easy to consume when appetite is suppressed — 20–40g protein post-workout
Don't train fasted if you feel fatigued — GLP-1-induced caloric restriction already creates a significant deficit

Nausea and Gastrointestinal Side Effects

GI side effects peak during dose escalation. During this period:

Reduce exercise intensity (walk instead of run)
Prioritize shorter sessions over none
Avoid high-intensity training when nausea is active
Return to full training once side effects subside (usually weeks 4–8)

Protein Targets

Protein is the key dietary variable for muscle preservation during GLP-1 therapy. Current evidence supports a minimum of 1.2 g/kg of body weight per day, with 1.6–2.0 g/kg being optimal for muscle-building goals. Given reduced appetite, this often requires deliberate effort:

Prioritize protein-dense foods (eggs, chicken, fish, Greek yogurt, cottage cheese)
Use protein supplements to fill gaps
Distribute protein evenly across 3–4 meals (rather than concentrating it at one meal)

Who Benefits Most from Exercise During GLP-1 Therapy?

The clinical benefit of exercise is universal, but some patient profiles have the most to gain:

Adults 50+: Age-related muscle loss (sarcopenia) accelerates during rapid weight loss. Exercise is non-negotiable for this group.
Patients with high muscle-to-fat ratios: Athletes or active individuals may lose disproportionate lean mass if they don't maintain training.
Patients planning to stop GLP-1 therapy: Exercise during treatment is the strongest predictor of not regaining weight after stopping.
Patients with metabolic syndrome: The anti-inflammatory effects of exercise compound the metabolic benefits of GLP-1 therapy.

Key Takeaways

Combining exercise — especially resistance training — with GLP-1 therapy is not optional for optimal outcomes. The medication handles appetite and hormonal regulation; exercise handles muscle preservation, fitness, and long-term sustainability.

Practical guidance for patients:

Start resistance training early — ideally from week 1 of GLP-1 therapy, even if the dose is low
Target 3–5 resistance training sessions per week for meaningful muscle preservation
Hit protein targets of at least 1.2 g/kg/day — this is as important as the exercise itself
Add aerobic exercise for cardiovascular and metabolic benefits, especially walking, cycling, or swimming
Expect reduced performance initially during dose escalation — this normalizes
Think beyond the scale — track body composition (DEXA or InBody if available), not just weight

For patients who successfully combine GLP-1 therapy with structured exercise and adequate protein, the combination is considerably more powerful than either approach alone — both during treatment and in the years that follow.

For additional context on what to expect when starting GLP-1 therapy, see our guide on starting GLP-1 medications.

References

Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024. DOI: 10.1111/dom.15728
Alissou, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70141
Fonseca VA, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine (The Lancet). 2024. DOI: 10.1016/j.eclinm.2024.102475 PubMed
Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. Sports Medicine. 2025. DOI: 10.1007/s40279-025-02386-0 PubMed
Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. 2025. PubMed

Last updated: 2026-03-25 Medical review: Dr. James Chen, MD, PhD, FACE